Understanding immune cells in bladder cancer treatment
Characterizing the immune infiltrate in muscle-invasive urothelial carcinoma
This study is looking at how the immune cells in bladder cancer respond to chemotherapy before surgery, to help find out which patients might do better with stronger treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10880631 on NIH RePORTER |
What this research studies
This research investigates how immune cells in muscle-invasive urothelial carcinoma respond to treatment, particularly focusing on the effectiveness of neoadjuvant chemotherapy. By analyzing tissue samples from patients before and after treatment, the study aims to identify biomarkers that can predict which patients will benefit from intensified therapy. The approach utilizes advanced techniques like spatial transcriptomics and proteomics to assess gene and protein expression in tumor and immune cells. This could lead to more personalized treatment strategies for patients with bladder cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with muscle-invasive urothelial carcinoma who are undergoing neoadjuvant chemotherapy.
Not a fit: Patients with non-muscle-invasive bladder cancer or those who are not candidates for chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that enhance survival rates for patients with muscle-invasive urothelial carcinoma.
How similar studies have performed: Preliminary evidence in other cancers suggests that studying immune cell infiltration can provide valuable insights, indicating potential success for this approach in urothelial carcinoma.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Collier, Katharine a. — Ohio State University
- Study coordinator: Collier, Katharine a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.